Elena Elimova

5.1k total citations
119 papers, 1.4k citations indexed

About

Elena Elimova is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Elena Elimova has authored 119 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pulmonary and Respiratory Medicine, 68 papers in Surgery and 52 papers in Oncology. Recurrent topics in Elena Elimova's work include Gastric Cancer Management and Outcomes (75 papers), Esophageal Cancer Research and Treatment (56 papers) and Gastrointestinal Tumor Research and Treatment (16 papers). Elena Elimova is often cited by papers focused on Gastric Cancer Management and Outcomes (75 papers), Esophageal Cancer Research and Treatment (56 papers) and Gastrointestinal Tumor Research and Treatment (16 papers). Elena Elimova collaborates with scholars based in Canada, United States and Japan. Elena Elimova's co-authors include Jaffer A. Ajani, Robert Kisilevsky, John B. Ancsin, Hironori Shiozaki, Roopma Wadhwa, Nikolaos Charalampakis, Walter A. Szarek, Mariela A. Blum, Manoop S. Bhutani and Maria Tolia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Elena Elimova

111 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elena Elimova Canada 21 710 534 529 364 185 119 1.4k
Tingyu Mou China 19 617 0.9× 360 0.7× 513 1.0× 508 1.4× 78 0.4× 48 1.5k
Yiyi Yu China 21 460 0.6× 273 0.5× 741 1.4× 447 1.2× 60 0.3× 99 1.4k
Jiuda Zhao China 17 573 0.8× 214 0.4× 764 1.4× 337 0.9× 59 0.3× 88 1.3k
Roberto Carlesi Italy 8 1.4k 2.0× 657 1.2× 1.0k 2.0× 383 1.1× 51 0.3× 15 2.0k
Zhixiang Zhou China 23 427 0.6× 597 1.1× 758 1.4× 300 0.8× 48 0.3× 117 1.4k
Yu‐Shang Yang China 18 447 0.6× 519 1.0× 281 0.5× 330 0.9× 39 0.2× 104 1.1k
Laura W. Goff United States 21 432 0.6× 526 1.0× 1.0k 1.9× 742 2.0× 67 0.4× 77 2.0k
Akitaka Makiyama Japan 17 412 0.6× 154 0.3× 715 1.4× 193 0.5× 59 0.3× 116 994
Benjamin A. Weinberg United States 18 450 0.6× 438 0.8× 1.1k 2.1× 293 0.8× 94 0.5× 128 1.5k
G. Kurteva United States 10 678 1.0× 254 0.5× 686 1.3× 180 0.5× 49 0.3× 26 1.0k

Countries citing papers authored by Elena Elimova

Since Specialization
Citations

This map shows the geographic impact of Elena Elimova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Elimova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Elimova more than expected).

Fields of papers citing papers by Elena Elimova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Elimova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Elimova. The network helps show where Elena Elimova may publish in the future.

Co-authorship network of co-authors of Elena Elimova

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Elimova. A scholar is included among the top collaborators of Elena Elimova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Elimova. Elena Elimova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Kane, Grainne M., Do‐Youn Oh, Jennifer L. Spratlin, et al.. (2024). A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).. Journal of Clinical Oncology. 42(16_suppl). 4115–4115. 2 indexed citations
2.
3.
Baskurt, Zeynep, Carly C. Barron, Xin Wang, et al.. (2024). Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes. Journal of Neuro-Oncology. 167(1). 111–122. 5 indexed citations
4.
Bolger, Jarlath, Nikolina Radulovich, Christine Ng, et al.. (2024). Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma. British journal of surgery. 111(1).
5.
Cleary, Sean P., Laura A. Dawson, Elena Elimova, et al.. (2024). Vascular Resection for Pancreas Cancer – 10-year Experience from a Single High Volume-center. Annals of Surgery. 1 indexed citations
6.
7.
Taylor, Kirsty, Jinfeng Zou, Marc Oliva, et al.. (2023). Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. European Journal of Cancer. 188. 29–38. 14 indexed citations
8.
9.
Chénard-Poirier, Maxime, Ravi Ramjeesingh, Vimoj Nair, et al.. (2023). Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023. Current Oncology. 30(9). 8172–8185.
10.
Tabernero, Josep, Lin Shen, Elena Elimova, et al.. (2022). HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncology. 18(29). 3255–3266. 45 indexed citations
11.
Anconina, Reut, Claudia Ortega, Ur Metser, et al.. (2021). Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 49(3). 1012–1020. 12 indexed citations
12.
Brockhausen, Inka, Elena Elimova, Ashley M. Woodward, & Pablo Argüeso. (2018). Glycosylation pathways of human corneal and conjunctival epithelial cell mucins. Carbohydrate Research. 470. 50–56. 15 indexed citations
13.
Elimova, Elena, et al.. (2016). Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clinic Proceedings. 91(9). 1307–1318. 1 indexed citations
14.
Elimova, Elena, Xuemei Wang, Elba Etchebehere, et al.. (2015). 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer. 51(17). 2545–2552. 47 indexed citations
15.
Elimova, Elena, Roopma Wadhwa, Hironori Shiozaki, et al.. (2015). Molecular Biomarkers in Gastric Cancer. Journal of the National Comprehensive Cancer Network. 13(4). e19–e29. 31 indexed citations
16.
Elimova, Elena. (2014). Medical management of gastric cancer: A 2014 update. World Journal of Gastroenterology. 20(38). 13637–13637. 31 indexed citations
17.
Wadhwa, Roopma, Elena Elimova, Hironori Shiozaki, et al.. (2014). Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Review of Anticancer Therapy. 14(4). 367–379. 10 indexed citations
18.
Shiozaki, Hironori, Kazuki Sudo, Lianchun Xiao, et al.. (2014). Distribution and Timing of Distant Metastasis after Local Therapy in a Large Cohort of Patients with Esophageal and Esophagogastric Junction Cancer. Oncology. 86(5-6). 336–339. 15 indexed citations
19.
Elimova, Elena, Robert Kisilevsky, & John B. Ancsin. (2009). Heparan sulfate promotes the aggregation of HDL‐associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. The FASEB Journal. 23(10). 3436–3448. 46 indexed citations
20.
Elimova, Elena, Robert Kisilevsky, Walter A. Szarek, & John B. Ancsin. (2004). Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. The FASEB Journal. 18(14). 1749–1751. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tingyu Mou Breakdown of academic impact, for papers by Yiyi Yu Breakdown of academic impact, for papers by Jiuda Zhao Breakdown of academic impact, for papers by Roberto Carlesi Breakdown of academic impact, for papers by Zhixiang Zhou Breakdown of academic impact, for papers by Yu‐Shang Yang Breakdown of academic impact, for papers by Laura W. Goff Breakdown of academic impact, for papers by Akitaka Makiyama Breakdown of academic impact, for papers by Benjamin A. Weinberg Breakdown of academic impact, for papers by G. Kurteva
Rankless by CCL
2026